BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

78.13 +1.64 (+2.14%)

Streaming Delayed Price Updated: 3:14 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Volume	1,857,920
Open	76.54
Bid (Size)	78.09 (300)
Ask (Size)	78.15 (300)
Prev. Close	76.49
Today's Range	76.02 - 78.18
52wk Range	27.53 - 78.44
Shares Outstanding	160,500,999
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

Today 14:27 EST

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500

Today 9:59 EST

As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the...

Via PredictStreet

Performance

YTD	N/A	N/A
1 Month	+9.3%	+9.3%
3 Month	+46.6%	+46.6%
6 Month	+77.6%	+77.6%
1 Year	+177.1%	+177.1%

More News

Earnings Scheduled For October 29, 2025 ↗

October 29, 2025

Via Benzinga

BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET

Today 7:30 EST

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

December 22, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗

December 22, 2025

Via The Motley Fool

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Via The Motley Fool

BridgeBio to Participate in December Investor Conferences

November 25, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

November 19, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 14, 2025

Via Benzinga

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

Via MarketMinute

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

November 08, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

Via MarketMinute

BridgeBio to Participate in November Investor Conferences

November 04, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

November 03, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

Via Investor's Business Daily

BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss ↗

October 29, 2025

Via Chartmill

BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

BridgeBio's Investigation Drug Outperforms Standard Therapy In Rare Calcium Disorder ↗

October 29, 2025

Via Benzinga

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results ↗

October 29, 2025

Via Stocktwits

BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High ↗

October 29, 2025

Via Investor's Business Daily

BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1

October 29, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 28, 2025

Via Benzinga

BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th

October 28, 2025

From BridgeBio Pharma, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is BridgeBio Pharma, Inc. - Common Stock publicly traded?

Yes, BridgeBio Pharma, Inc. - Common Stock is publicly traded.

What exchange does BridgeBio Pharma, Inc. - Common Stock trade on?

BridgeBio Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BridgeBio Pharma, Inc. - Common Stock?

The ticker symbol for BridgeBio Pharma, Inc. - Common Stock is BBIO on the Nasdaq Stock Market

What is the current price of BridgeBio Pharma, Inc. - Common Stock?

The current price of BridgeBio Pharma, Inc. - Common Stock is 78.13

When was BridgeBio Pharma, Inc. - Common Stock last traded?

The last trade of BridgeBio Pharma, Inc. - Common Stock was at 01/02/26 03:14 PM ET

What is the market capitalization of BridgeBio Pharma, Inc. - Common Stock?

The market capitalization of BridgeBio Pharma, Inc. - Common Stock is 12.54B

How many shares of BridgeBio Pharma, Inc. - Common Stock are outstanding?

BridgeBio Pharma, Inc. - Common Stock has 13B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.